Arbutus Biopharma
ABUSArbutus Biopharma Corporation is a publicly traded (NASDAQ: ABUS) biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.It is headquartered in Vancouver, British Columbia and has research facilities in Warminste …
© Wikipedia /
Creative Commons CC-BY-SA 3.0 more at Wikipedia
Insider trades and stock quote 2023-2025
All insider trades at Arbutus Biopharma
Subscribe RSS| Date | Type | Insider | Position | Ø-Price | Volume |
|---|---|---|---|---|---|
| 2/4/2025 | Sell | Naftzger, J. Christopher | General Counsel and CCO | $3.3 | $37,206 |
| 2/4/2025 | Sell | Mcelhaugh, Michael J. | Interim President & CEO | $3.3 | $78,103 |
| 2/4/2025 | Sell | Sims, Karen | Chief Medical Officer | $3.3 | $63,519 |
| 2/4/2025 | Sell | Hastings, David C. | Chief Financial Officer | $3.3 | $72,827 |
| 8/14/2024 | Sell | Manchester, Keith S. | Director | $3.7 | $32,637 |
All information without guarantee! No recommendation/consultation!
© U.S. Securities and Exchange Commission (SEC)